A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
Phase 1
Not yet recruiting
- Conditions
- Graft Versus Host Disease
- Interventions
- Biological: VM-001 1X10^6 cells/kgBiological: VM-001 1X10^6 cells/kg four doseBiological: VM-001 5X10^6 cells/kgBiological: VM-001 1X10^6 cells/kg two doseBiological: VM-001 3X10^6 cells/kg
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- ViGenCell Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05276076
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients
Phase 2
- Conditions
- Extranodal NK/T-cell Lymphoma
- Interventions
- Biological: VT-EBV-NOther: Placebo
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- ViGenCell Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03671850
- Locations
- π°π·
Keimyung University Daegu Dongsan Hospital, Daegu, Korea, Republic of
π°π·Hallym Univ. Medical Center, Gyeonggi-do, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath